title: Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland.
abstract: OBJECTIVE
  To describe nation-wide secular trends in statin use.
  
  
  METHODS
  Reimbursed prescriptions for lipid lowering drugs between 1995 and 2005 in Finland were retrieved from the nation-wide Prescription Register. The 1 year prevalence and incidence of statin use stratified by gender and age of users were measured for each calendar year. The relative changes (RR) in the incidence and the prevalence were calculated by using the year 1995 as a reference.
  
  
  RESULTS
  The 1 year prevalence increased 11-fold (95% confidence interval 11.2, 11.5), i.e. from 7.8 per 1000 inhabitants in 1995 to 88.9 in 2005. The incidence increased five-fold (95% CI 4.9, 5.1) from 355 per 100 000 inhabitants to 1772 during the respective years. The prevalence and incidence were the highest among persons aged 65-74 years. The largest relative increase in incidence was found among those aged >/= 75 years, in both females (RR 14.1, 95% CI 13.0, 15.3) and males (RR 14.0, 95% CI 12.5, 15.7). Since 2002 the prevalence has been higher among females (P < 0.05).
  
  
  CONCLUSIONS
  As statin use has increased particularly among the elderly, further studies on the benefits in real life situation are needed in this age group.
authors.affiliation: Graduate School of Clinical Drug Research, University of Turku, Turku, Finland. paivi.ruokoniemi@utu.fi
authors.forename: Päivi
authors.initials: P
authors.lastname: Ruokoniemi
authors.forename: Arja
authors.initials: A
authors.lastname: Helin-Salmivaara
authors.forename: Timo
authors.initials: T
authors.lastname: Klaukka
authors.forename: Pertti J
authors.initials: PJ
authors.lastname: Neuvonen
authors.forename: Risto
authors.initials: R
authors.lastname: Huupponen
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D003327:Coronary Disease / Q000453:epidemiology / Q000517:prevention & control*; D017723:Drug Utilization Review / Q000639:trends; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references.citation: BMJ. 1998 Oct 24;317(7166):1134-5
references.pmid: 9784452
references.citation: N Engl J Med. 1998 Nov 5;339(19):1349-57
references.pmid: 9841303
references.citation: Eur J Clin Pharmacol. 1997;53(3-4):185-9
references.pmid: 9476029
references.citation: Am Heart J. 2001 Jun;141(6):957-63
references.pmid: 11376310
references.citation: N Engl J Med. 1996 Oct 3;335(14):1001-9
references.pmid: 8801446
references.citation: Eur J Clin Pharmacol. 2001 Jul;57(4):343-8
references.pmid: 11549214
references.citation: Eur J Clin Pharmacol. 2007 Feb;63(2):197-203
references.pmid: 17200832
references.citation: Br J Clin Pharmacol. 2007 Oct;64(4):476-81
references.pmid: 17441934
references.citation: J Clin Epidemiol. 1996 Dec;49(12):1453-57
references.pmid: 8970497
references.citation: Am J Med. 2000 Apr 15;108(6):496-9
references.pmid: 10781783
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: Scand Cardiovasc J. 2004 Dec;38(6):340-4
references.pmid: 15804799
references.citation: Br J Clin Pharmacol. 2001 Sep;52(3):307-11
references.pmid: 11560563
references.citation: Lancet. 1994 Nov 19;344(8934):1383-9
references.pmid: 7968073
references.citation: Br J Clin Pharmacol. 2002 Apr;53(4):379-85
references.pmid: 11966669
references.citation: Lancet. 2001 Mar 31;357(9261):995-1001
references.pmid: 11293642
references.citation: Lancet. 2002 Nov 23;360(9346):1623-30
references.pmid: 12457784
references.citation: Br J Clin Pharmacol. 2005 Nov;60(5):543-51
references.pmid: 16236045
references.citation: Eur Heart J. 2006 Feb;27(3):296-301
references.pmid: 16284204
references.citation: Br J Clin Pharmacol. 2000 May;49(5):463-71
references.pmid: 10792204
references.citation: Lancet. 2011 Dec 10;378(9808):2013-2020
references.pmid: 22115874